Inclusion of cryoprecipitate, pathogen-reduced, in the WHO model lists of essential medicines for adults and children: a call for action

Affiliations

¹ McLean, Virginia, VA, United States of America.
² Blood and other Products of Human Origin Team, WHO Headquarters, Geneva, Switzerland.
³ Association Luxembourgeoise des Hémophiles, Luxembourg City, Luxembourg.
⁴ Sanquin Consulting Services, Amsterdam and Academic Institute IDTM, Groningen, the Netherlands.
⁵ Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
⁶ International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.

Jay S Epstein et al. Blood Transfus. 2024 Nov.

. 2024 Nov;22(6):481-483.

doi: 10.2450/BloodTransfus.687. Epub 2024 Jan 31.

¹ McLean, Virginia, VA, United States of America.
² Blood and other Products of Human Origin Team, WHO Headquarters, Geneva, Switzerland.
³ Association Luxembourgeoise des Hémophiles, Luxembourg City, Luxembourg.
⁴ Sanquin Consulting Services, Amsterdam and Academic Institute IDTM, Groningen, the Netherlands.
⁵ Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
⁶ International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.

No abstract available

Conflict of interest statement

The Authors declare no conflicts of interest.

1. New World Bank country classifications by income level: 2022–2023. [Accessed on 25/10/2023]. Available at: https://blogs.worldbank.org/opendata/new-world-bank-country-classificati....
1. Pierce GF, Adediran M, Diop S, Dunn AL, Ekiaby ME, Kaczmarek R, et al. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022;9:e689–e697. doi: 10.1016/S2352-3026(22)00209-5. - DOI - PubMed
1. Srivastava A. The case for equitable haemophilia care. Lancet Haematol. 2021;8:e626. doi: 10.1016/S2352-3026(21)00132-0. - DOI - PubMed
1. Batt K, Schultz BG, Caicedo J, Hollenbeak CS, Agrawal N, Chatterjee S, et al. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab. Curr Med Res Opin. 2022;38:1685–1693. doi: 10.1080/03007995.2022.2105072. - DOI - PubMed
1. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia. Haemophilia. (3rd edition) 2020;26(Suppl 6):1–158. doi: 10.1111/hae.14046. - DOI - PubMed